Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization.

IF 3 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2026-10-01 Epub Date: 2026-08-01 DOI:10.1007/s10147-026-03141-9

Yukako Takehara, Yu Saito, Yuji Morine, Shinichiro Yamada, Hiroki Teraoku, Yuhei Waki, Tetsuya Ikemoto, Mitsuo Shimada

{"title":"Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization.","authors":"Yukako Takehara, Yu Saito, Yuji Morine, Shinichiro Yamada, Hiroki Teraoku, Yuhei Waki, Tetsuya Ikemoto, Mitsuo Shimada","doi":"10.1007/s10147-026-03141-9","DOIUrl":null,"url":null,"abstract":"Background: Local recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) or selective transarterial chemoembolization (sTACE) is relatively common. This study aimed to examine salvage hepatectomy as a treatment of such recurrences.Methods: We retrospectively analyzed 382 patients who underwent up-front hepatectomy for treatment of HCC and 44 patients who underwent salvage hepatectomy for treatment of local recurrence after RFA or sTACE. Propensity score matching analysis was performed to account for group differences.Results: Mean time between the initial treatment and salvage hepatectomy was 3.5 ± 3.0 years. At the time of salvage hepatectomy, macroscopic vessel invasion was present in 15 patients (34.1%) and mean tumor size was significantly larger (3.0 ± 1.7 cm vs. 2.4 ± 1.1 cm; p = 0.097). Propensity score matching resulted in 33 matched pairs. After matching, 5-year overall survival did not significantly differ between the salvage and up-front hepatectomy groups. Multivariate analysis in the salvage hepatectomy group showed that serum α-fetoprotein concentration > 100 ng/mL was the only independent predictor of overall and disease-free survival.Conclusions: Salvage hepatectomy appears to be feasible for selected patients with local recurrence of HCC after RFA or sTACE.","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2374-2381"},"PeriodicalIF":3.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-026-03141-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Local recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) or selective transarterial chemoembolization (sTACE) is relatively common. This study aimed to examine salvage hepatectomy as a treatment of such recurrences.

Methods: We retrospectively analyzed 382 patients who underwent up-front hepatectomy for treatment of HCC and 44 patients who underwent salvage hepatectomy for treatment of local recurrence after RFA or sTACE. Propensity score matching analysis was performed to account for group differences.

Results: Mean time between the initial treatment and salvage hepatectomy was 3.5 ± 3.0 years. At the time of salvage hepatectomy, macroscopic vessel invasion was present in 15 patients (34.1%) and mean tumor size was significantly larger (3.0 ± 1.7 cm vs. 2.4 ± 1.1 cm; p = 0.097). Propensity score matching resulted in 33 matched pairs. After matching, 5-year overall survival did not significantly differ between the salvage and up-front hepatectomy groups. Multivariate analysis in the salvage hepatectomy group showed that serum α-fetoprotein concentration > 100 ng/mL was the only independent predictor of overall and disease-free survival.

Conclusions: Salvage hepatectomy appears to be feasible for selected patients with local recurrence of HCC after RFA or sTACE.

查看原文本刊更多论文

射频消融或选择性经动脉化疗栓塞后局部复发肝切除术的临床影响。

背景：肝细胞癌（HCC）在射频消融（RFA）或选择性经动脉化疗栓塞（sTACE）后局部复发是相对常见的。本研究旨在探讨挽救性肝切除术作为这种复发的治疗方法。方法：我们回顾性分析了382例接受肝切除术治疗HCC的患者和44例接受补救性肝切除术治疗RFA或sTACE后局部复发的患者。进行倾向评分匹配分析以解释组间差异。结果：从初始治疗到挽救性肝切除术的平均时间为3.5±3.0年。在补救性肝切除术时，15例患者（34.1%）出现宏观血管侵犯，平均肿瘤大小明显增大（3.0±1.7 cm vs. 2.4±1.1 cm; p = 0.097）。倾向评分匹配结果为33对。匹配后，挽救性肝切除术组和预先肝切除术组的5年总生存率无显著差异。抢救性肝切除术组的多因素分析显示，血清α-胎蛋白浓度bbb100 ng/mL是总生存率和无病生存率的唯一独立预测因子。结论：对于RFA或sTACE术后局部复发的肝癌患者，挽救性肝切除术似乎是可行的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.